Triflusal

CAS No. 322-79-2

Triflusal ( Triflusal, Disgren, Grendis, Aflen, Triflux )

Catalog No. M14050 CAS No. 322-79-2

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 35 In Stock
10MG 58 In Stock
25MG 106 In Stock
50MG 177 In Stock
100MG 295 In Stock
200MG 444 In Stock
500MG 710 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Triflusal
  • Note
    Research use only, not for human use.
  • Brief Description
    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.
  • Description
    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA).
  • Synonyms
    Triflusal, Disgren, Grendis, Aflen, Triflux
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE; TXA2R
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    322-79-2
  • Formula Weight
    248.16
  • Molecular Formula
    C10H7F3O4
  • Purity
    >98%(HPLC)
  • Solubility
    Ethanol: 50 mg/mL (201.48 mM); DMSO: 50 mg/mL (201.48 mM)
  • SMILES
    O=C(O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O
  • Chemical Name
    2-acetyloxy-4-(trifluoromethyl)benzoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Acta Crystallographica Section A, 49 ( Pt 1), 10-22 (1993)
molnova catalog
related products
  • PDE9-IN-(S)-C33

    PDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.

  • GSK-256066

    A potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively.

  • Dazonone

    Dazonone is a specific PDE III inhibitors.